| DIRECT COMPETITOR COMPARISON | |
| GTXI | AZN | LLY | GSK | Industry | | Market Cap: | 141.31M | 66.28B | 42.46B | 107.64B | 104.07M | | Employees: | 147 | 65,000 | 40,500 | 99,003 | 68 | | Qtrly Rev Growth (yoy): | 18.10% | 5.50% | 6.80% | 14.90% | 19.70% | | Revenue (ttm): | 14.05M | 32.05B | 21.11B | 44.80B | 14.01M | | Gross Margin (ttm): | -157.04% | 82.24% | 82.33% | 76.27% | 65.67% | | EBITDA (ttm): | -48.07M | 13.52B | 7.74B | 17.66B | -12.30M | | Oper Margins (ttm): | -354.81% | 37.85% | 30.97% | 34.30% | -149.46% | | Net Income (ttm): | -49.25M | 7.22B | -216.00M | 8.05B | N/A | | EPS (ttm): | -1.353 | 4.98 | -0.197 | 3.15 | -0.33 | | P/E (ttm): | N/A | 9.18 | N/A | 13.48 | 16.37 | | PEG (5 yr expected): | N/A | N/A | 3.98 | 3.06 | 1.31 | | P/S (ttm): | 10.11 | 2.03 | 2.00 | 2.35 | 9.43 |
|
| AZN = AstraZeneca plc | | LLY = Eli Lilly & Co. | | GSK = GlaxoSmithKline plc | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.68 | 0.59% | 57.37B | 12.36 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.40 | 0.98% | 13.71B | 15.86 | | Genzyme Corp. | GENZ | 51.34 | 1.26% | 13.62B | 29.27 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.185 | 0.16% | 41.56B | 17.86 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.97 | 2.39% | 9.09B | 1040.20 | | Teva Pharmaceutical Industries Limited | TEVA | 53.29 | 0.95% | 46.95B | 48.76 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.53 | 1.19% | 3.98B | 19.35 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.83 | 0.00% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.1801 | 1.74% | 5.56B | 111.53 | | Pfizer Inc. | PFE | 18.68 | 2.81% | 150.74B | 15.51 | | Johnson & Johnson | JNJ | 63.41 | 0.91% | 174.95B | 13.85 | | GlaxoSmithKline plc | GSK | 42.46 | 2.39% | 107.64B | 13.48 | | Sanofi-Aventis | SNY | 39.28 | 3.48% | 102.56B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 56.29 | 1.24% | 127.85B | 16.85 | | RHHBY.PK | 41.43 | 1.25% | N/A | N/A | | AstraZeneca plc | AZN | 45.71 | 1.96% | 66.28B | 9.18 | | Abbott Laboratories | ABT | 54.44 | -0.09% | 84.20B | 14.75 | | Bristol-Myers Squibb Co. | BMY | 24.84 | -1.86% | 49.21B | 12.85 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|